JBS N.V. (JBS): A Bull Case Theory

Core Thesis - JBS N.V. is viewed positively due to its strong market position and growth potential in the protein sector, with shares trading at $16.18 and a trailing P/E of 15.53 and forward P/E of 3.87 [1][2] Company Overview - JBS S.A. operates as a global leader in protein production, with extensive operations across beef, pork, poultry, and diversified products, including plant-based proteins, leather, and biodiesel [3] - The company has over 250 facilities and operates in more than 180 countries, providing significant bargaining power and distribution advantages [3] Market Dynamics - There is strong secular demand for protein driven by population growth and rising incomes in emerging markets, which supports long-term growth [4] - Geographic expansion, particularly in Europe through acquisitions, is expected to enhance market share [4] Financial Performance - In Q3 2025, JBS reported net sales of approximately $22.6 billion, reflecting a ~13% increase, although profit and EBITDA declined due to tight U.S. beef supplies and rising input costs [5] - The company is pursuing around $2 billion in annual capital expenditures for facility modernization and higher-margin segments, supported by a dual NYSE listing for cheaper capital [5] Competitive Landscape - JBS's competitive strength is derived from its scale, integration, and diversification, but it faces moderate competition from rivals like Tyson Foods, Marfrig, and BRF, as well as changing consumer preferences towards alternative proteins [5] - The company’s leverage is approximately 2.4x, indicating a need for careful financial discipline amidst cyclical risks [5] Risks and Opportunities - Key risks include commodity cycles, disease outbreaks, ESG/legal pressures, and trade disruptions, which could significantly impact profitability [6] - Upside potential exists through European acquisitions, operational improvements, and growth in prepared foods or plant-based proteins, while downside risks are linked to cyclicality and regulatory pressures [6] - JBS's valuation appears attractive with a forward P/E of ~9.1 and a strong return on equity of ~23.7%, although earnings volatility necessitates caution [6]